AMEX · Biotechnology

Calidi Biotherapeutics, Inc. (CLDI) Stock

$1.03 -0.96% AMEX: CLDI Healthcare

Valuation

MetricValue
Price$1.03
Market Cap$2.66M
P/E Ratio-0.02
P/B Ratio0.49
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$27.84
52-Week Low$1.01
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-372.86%
ROA-242.55%
ROCE-449.99%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.62
Current Ratio1.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-10.0M$-23.0M$-29.0M$-22.0M$-20.0M
Net Profit$-11.0M$-25.0M$-29.0M$-22.0M$-20.0M
EPS$226.56$-5740.80$-3321.76$-571.20$-95.20
Op Margin-2334.5%-51395.6%———

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$3.0M$3.0M$10.0M$14.0M$9.0M
Total Liabilities$26.0M$53.0M$18.0M$12.0M$5.0M
Cash$2.0M$0$2.0M$10.0M$6.0M
Borrowings$5.0M$6.0M$7.0M$7.0M$3.0M

Latest News

Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers GlobeNewswire · Jul 21, 2026 Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split MT Newswires · Jul 20, 2026 Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 GlobeNewswire · Jul 20, 2026 Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 GlobeNewswire · Jul 8, 2026 Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit GlobeNewswire · Jun 24, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-8.0M$-13.0M$-27.0M$-20.0M$-21.0M
Investing Cash Flow$0$-1.0M$-1.0M$0$0
Financing Cash Flow$8.0M$11.0M$1.0M$0$-1.0M
Net Cash Flow$2.0M$-2.0M$2.0M$8.0M$-4.0M
Free Cash Flow$-8.0M$-14.0M$-28.0M$-20.0M$-21.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.04
FCF Yield-638.03%
Quick Ratio1.68
Interest Coverage-114.43
Return 1Y-98.21%
Return 3Y-99.99%
Return 5Y—

Ownership

Insiders Held1.87%
Institutions Held10.46%
Institutions Float Held10.66%
Institutional HolderSharesReport Date
Armistice Capital, LLC879,0002026-03-31
Sabby Management, LLC434,9032026-03-31
Warberg Asset Management LLC250,0002026-03-31
HighTower Advisors, LLC83,5232026-03-31
Virtu Financial LLC75,7692026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. is led by CEO Eric E. Poma, employs 28 people, headquartered in US, publicly traded since 2021.

Calidi Biotherapeutics, Inc. (CLDI) stock trades at $1.03 with a market capitalization of $2.66M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.49, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.01 and $27.84, and currently trades 96.3% below its 52-week high.

On profitability, Calidi Biotherapeutics, Inc. generates a return on equity (ROE) of -372.86%, return on capital employed of -449.99%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides